NIAGEN BIOSCIENCE INC (NAGE)
Consumer Staples · Health & Wellness / Biotechnology · NASDAQ
Niagen Bioscience is an anti-aging bioscience company advancing NAD+ science through its proprietary Niagen ingredient used in supplements, compounded medicines, and clinical research.
What NIAGEN BIOSCIENCE INC does
Niagen Bioscience is a global bioscience company focused on healthy aging through the research, development, and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. It operates through consumer products, ingredient supply, and pharmaceutical development segments, featuring its proprietary Niagen (nicotinamide riboside chloride) ingredient. The company sells dietary supplements directly to consumers under the Tru Niagen brand and supplies pharmaceutical-grade ingredients for compounding and clinical research.
Recent developments
In July 2026, the company introduced NB4168, a lead investigational therapeutic candidate for Ataxia-Telangiectasia, which has received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations. Additionally, the company launched a Niagen Plus telehealth platform to enable patient access to injectable Niagen.
From NIAGEN BIOSCIENCE INC's filing of 2026-08-04.
Themes: healthy aging, NAD+ biology, dietary supplements, telehealth, rare disease therapeutics, compounding pharmacy supply
Fundamentals
- Price$2.51 as of 2026-10-20 close
- Market cap$199M as of 2026-07-30 (share count; price 2026-10-20)
- 1-year return-65.2% 2025-10-20 close $7.21 → 2026-10-20 close $2.51
- P/E13.21 as of 2026-10-20
- Net margin+13.4% FY2025, SEC XBRL
- Gross margin+64.3% FY2025, SEC XBRL
- ROE+22.7% FY2025, SEC XBRL
- ROICn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+29.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+21.6% SEC XBRL
- Beta1.49 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How NAGE compares in its sector
- price-to-earnings ratiobottom 25% 85 covered Consumer Staples peers, as of 2026-10-20
- net profit margintop 25% 105 covered Consumer Staples peers, as of 2026-09-03
- operating marginmiddle range 98 covered Consumer Staples peers, as of 2026-09-03
- gross margintop 25% 93 covered Consumer Staples peers, as of 2026-09-03
- return on equitytop 25% 106 covered Consumer Staples peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 109 covered Consumer Staples peers
Position among covered Consumer Staples companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $30M | $19M | $700000 | $963000 | $0.01 | $3M† |
| Q1 FY2026 2026-03-31 | $31M | $20M | $2M | $6M | $0.07 | -$1M |
| Q4 FY2025 2025-12-31 | $34M† | $22M† | $4M† | $4M† | $0.05† | $679000† |
| Q3 FY2025 2025-09-30 | $34M | $22M | $4M | $5M | $0.05 | $4M† |
| Q2 FY2025 2025-06-30 | $31M | $20M | $3M | $4M | $0.04 | $1M† |
| Q1 FY2025 2025-03-31 | $30M | $19M | $5M | $5M | $0.06 | $8M |
| Q4 FY2024 2024-12-31 | $29M† | $18M† | $7M† | $7M† | $0.09† | $9M† |
| Q3 FY2024 2024-09-30 | $26M | $16M | $2M | $2M | $0.02 | $3M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$67M includes restricted cash (the filer tags no unrestricted total)
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How NIAGEN BIOSCIENCE INC looks technically
NIAGEN BIOSCIENCE INC (NAGE) is trading 40.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 235 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 3.1% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 40.6% below its 200-day average, the long-term trend line — a long-term downtrend | -40.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.96 | $2.96 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.22 | $4.22 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 3.12. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 235 trading days ago — a "death cross", a bearish long-term signal | 235 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with sellers in control | 39.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30) | 31.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.44 to $2.92) — its "stochastic" reading is 15 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 15.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.95 | $7.95 |
|---|---|---|
| From the 52-week high | it is 68.4% below its 52-week high (its highest price of the past year) | -68.4% |
| Above the 52-week low | it is 3.1% above its 52-week low (its lowest price of the past year) | +3.1% |
| Below the 52-week high | it is 68.4% below its highest point of the past year | 68.4% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $23.66 (set on 2021-02-25) | $23.66 |
| Given back of the 52-week move | over the past year its closes ranged ($2.49 to $7.60), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.65 to $5.81. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.4% |
| From the all-time high | it is 89.4% below its all-time high | -89.4% |
| Nearest price level | it is trading 17.5% below a resistance level at $2.95 — a price it turned at twice since 2026-08-17, most recently on 2026-09-15. Since 2024-10-21 it has 0 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +17.5% |
| All-time low | its lowest closing price on record is $0.33 (set on 2009-08-03) | $0.33 |
| Above the all-time low | it is 660.6% above its all-time low | +660.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 85% of the past ~6 months) | 85th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0945 between its high and its low — about 3.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0945 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.37 and $3.10 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.37 – $2.73 – $3.10 |
| Typical daily range (% of price) | its price moves about 3.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.8% |
| Stretch from the 200-day average | it is trading 18.1 daily ranges below its 200-day average price (40.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 18.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 10.7% below the previous close 53 sessions ago and has not traded back through the level it left behind at 3.47 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.7% |
| Gap filled | a 2.9% gap up opened on 2026-08-03 has been "filled" 53 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 53 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +0.8% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.0 percentage points (the stock lost 16.1% while the market gained 1.0%) | -17.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 29.2 percentage points (the stock lost 25.5% while the market gained 3.6%) | -29.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 57.0 percentage points (the stock lost 48.5% while the market gained 8.5%) | -57.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 79.7 percentage points (the stock lost 65.2% while the market gained 14.6%) | -79.8% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 20% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.0% of the share price. | -19.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 42% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.34 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -42.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.95 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | -15.1% |
Price levels it has turned at before
NAGE last closed at $2.51 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 13 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.95 | Resistance | 17.5% above the last close | turned there twice · 2026-08-17 to 2026-09-15 |
| $3.63 | Resistance | 44.8% above the last close | turned there twice · 2026-07-07 to 2026-08-04 |
| $4.73 | Resistance | 88.5% above the last close | turned there twice · 2026-02-23 to 2026-03-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $3.12.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 21 trading days, since 2026-09-22.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market · Stretched far below its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$12.08 range $8.50 – $22.00; median $10.50
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NAGE
- Consensus EPS estimate-$0.03 next reporting period, as of 2026-10-17
- Estimate change, 30 days-$0.02 from -$0.01, on 2026-09-12, 35-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependency on revenue from the Tru Niagen product line.","Operating in a highly competitive health, wellness, and dietary supplement market.","Risks associated with the regulatory environment for dietary supplements and pharmaceutical ingredients."]
What changed in the latest 10-Q
AI-assisted comparison of NAGE's 10-Q filed 2026-05-06 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference year changed from 2024 to 2025 in Annual Report citation (newer: December 31, 2025, filed March 4, 2026; older: December 31, 2024, filed March 4, 2025)
- Comparison period changed from three and nine months ended September 30, 2025 vs. 2024 to three months ended March 31, 2026 vs. 2025
- New 'Recent Developments' section added: Disposal of Analytical Reference Standards and Services Segment, completed February 2026 for ~$6.0 million with ~$4.8 million gain recognized
- Statement that analytical reference standards and services revenue is no longer included in ongoing operating results following closing date
- Removed:
- Detailed company history narrative removed (e.g., '2013 commercialized food-grade Niagen®', '2017 launched Tru Niagen®', '2024 launched Niagen Plus')
- References to specific regulatory approvals and jurisdictions removed (Health Canada, European Commission, Turkish Ministry of Agriculture, ANVISA, FSANZ)
- Statement about NAD+ decline 'by up to 65% between ages 30 and 70'
- List of disease areas studied changed from 'Alzheimer's disease, Parkinson's disease' to 'Ataxia-Telangiectasia, neurodegenerative diseases'
- Reference to 'more than 300 research collaborations' and specific institution names (NIH, Cornell, Dartmouth, Harvard, MIT, Cambridge, Mayo Clinic, Chiba, Sun Yat-sen) removed
- References to Scientific Advisory Board and specific advisors (Roger Kornberg, Charles Brenner) removed
- Previous 'Recent Developments' section content removed: Employee Stock Purchase Plan (June 24, 2025) and Purchase Commitments (Grace Supply Agreement, July 25, 2025)
- Reworded:
- Company description shifted from 'Our team, which includes world-renowned scientists, is pioneering research' to 'Our operations are centered on the research, development and commercialization' (more operational focus)
- NAD+ description expanded from basic definition to include 'may also be impacted by lifestyle and certain disease states' (removed specific percentage decline reference)
- Changed from 'novel form of vitamin B3' descriptor to direct reference as NAD+ precursor without vitamin B3 characterization
- Business platform description restructured: removed narrative history; added formal three-pillar structure (Consumer Products, Ingredients, Pharmaceutical Development)
- Pharmaceutical development section newly added as distinct business segment with statement 'we do not currently generate revenue from these activities'
- Reorganized and simplified regulatory approvals language; removed medical foods and FSANZ references
- Notes:
- The newer filing text appears truncated at 'In add' at end of Recent Developments section, preventing full assessment of content that may follow
- Comparison is between Q3 2025 filing (9/30/2025 data) and Q1 2026 filing (3/31/2026 data), representing different fiscal periods within different years
Risk Factors
- Added:
- Added risk factor bullet point: 'We are subject to potential payment processing risk.' under Risks Related to our Products section (filed 2026-05-06)
- Added risk factor bullet point: 'Compliance with stringent and changing global privacy and data security laws and regulations may increase our operating costs, expose us to liability, and restrict our ability to collect, use, transfer, and otherwise process data critical to our business. Any actual or perceived failure to comply could materially adversely affect our business, financial condition, or operations.' under Risks Related to Regulatory Approval section (filed 2026-05-06)
- Removed:
- Removed risk factor bullet point: 'We have a history of operating losses, may need additional financing to meet our future long-term capital requirements and may be unable to raise sufficient capital on favorable terms or at all.' from the beginning of Risks Related to our Company and Business list in summary section (filed 2025-11-04 version had this first)
- Reworded:
- Reordered risk factors in the summary section under 'Risks Related to our Company and Business:' - the capital requirements/financing risk was moved from first position to last position (filed 2026-05-06 vs filed 2025-11-04)
- Cyber security risk factor wording changed from 'Our business could be negatively impacted by cyber security incidents or threats, including without limitation a material interruption to our operations and our IT systems, a material interruption to our clinical trials, harm to our reputation, significant fines, penalties, litigation, and liabilities, regulatory investigations or lawsuits, including class actions, breach or triggering of data protection laws, privacy policies and data protection obligations, or a loss of revenue, customers or sales.' to 'Our business could be negatively impacted by cyber security incidents or threats, which could lead to data breaches, material interruption to our operations, manufacturing or laboratory systems, clinical trials, and IT systems, and violations of statutory and contractual privacy, confidentiality and data security obligations. This could result in significant fines, penalties, litigation, and liabilities, regulatory investigations or lawsuits, including class actions, reputational harm, and loss of revenue, customers or sales.' (filed 2026-05-06)
- Privacy/data security compliance risk factor wording significantly revised from 'Compliance with stringent and changing global privacy and data security laws and regulations could result in additional costs and liabilities to us or inhibit our ability to collect and, if applicable, process data globally, and the failure or perceived failure to comply with such laws and regulations could have a material adverse effect on our business, financial condition or results of operations.' to new version emphasizing increased operating costs, exposure to liability, and data processing restrictions (filed 2026-05-06)
- Changed 'Environmental, social and governance matters may impact our business and reputation.' to 'Environmental, social and governance matters and any related reporting obligations may impact our business and reputation.' - added reference to reporting obligations (filed 2026-05-06)
- Notes:
- The newer filing text is truncated at the end of the detailed risk factor section, so only the summary section and initial detailed risk factors can be fully compared
- The older filing text is also truncated, so complete comparison of all detailed risk factors is not possible
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for NAGE — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NAGE as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,308,412
- Reported value $23,313,837
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NAGE's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NAGE had 3,874,102 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
NAGE had 4.90% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.86 days to cover at the same settlement.
- Reported short interest (shares) 3,874,102
- Short interest (% of shares outstanding) 4.90%
- Prior settlement (shares) 3,996,318
- Reported change -3.06%
- Days to cover (reported) 9.86
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Haleon
- Nestlé Health Science
- GNC
- Vitamin Shoppe
- NOW Foods
- Thorne HealthTech
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NAGE vs…
NIAGEN BIOSCIENCE INC is found in…
Frequently asked questions
What does NIAGEN BIOSCIENCE INC (NAGE) do?
Niagen Bioscience is a global bioscience company focused on healthy aging through the research, development, and commercialization of nicotinamide adenine dinucleotide (NAD+) precursors. It operates through consumer products, ingredient supply, and pharmaceutical development segments, featuring its proprietary Niagen (nicotinamide riboside chloride) ingredient.
What sector is NIAGEN BIOSCIENCE INC (NAGE) in?
NIAGEN BIOSCIENCE INC (NAGE) is classified in the Consumer Staples sector. Its industry is Health & Wellness / Biotechnology. It trades on NASDAQ.
Who are NIAGEN BIOSCIENCE INC's (NAGE) competitors?
Notable peers of NIAGEN BIOSCIENCE INC (NAGE) include Haleon, Nestlé Health Science, GNC, Vitamin Shoppe and NOW Foods. This peer set is informational only — not financial advice.
Is NIAGEN BIOSCIENCE INC (NAGE) overbought or oversold right now?
NIAGEN BIOSCIENCE INC (NAGE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 31, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NAGE come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.